WO2022143911A1 - 一种纤溶酶抑制剂、其制备方法及应用 - Google Patents
一种纤溶酶抑制剂、其制备方法及应用 Download PDFInfo
- Publication number
- WO2022143911A1 WO2022143911A1 PCT/CN2021/143140 CN2021143140W WO2022143911A1 WO 2022143911 A1 WO2022143911 A1 WO 2022143911A1 CN 2021143140 W CN2021143140 W CN 2021143140W WO 2022143911 A1 WO2022143911 A1 WO 2022143911A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- unsubstituted
- hydrogen
- alkyl
- reaction
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 110
- 229940122791 Plasmin inhibitor Drugs 0.000 title description 2
- 239000002806 plasmin inhibitor Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 149
- 239000000203 mixture Substances 0.000 claims abstract description 42
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 239000000651 prodrug Substances 0.000 claims abstract description 19
- 229940002612 prodrug Drugs 0.000 claims abstract description 19
- 230000015271 coagulation Effects 0.000 claims abstract description 10
- 238000005345 coagulation Methods 0.000 claims abstract description 10
- 230000023597 hemostasis Effects 0.000 claims abstract description 4
- -1 amino, hydroxy Chemical group 0.000 claims description 73
- 229910052739 hydrogen Inorganic materials 0.000 claims description 50
- 239000001257 hydrogen Substances 0.000 claims description 50
- 150000002431 hydrogen Chemical class 0.000 claims description 40
- 229910052757 nitrogen Inorganic materials 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 25
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- 125000003118 aryl group Chemical group 0.000 claims description 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 17
- 150000004677 hydrates Chemical class 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 15
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 125000001188 haloalkyl group Chemical group 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 9
- 208000032843 Hemorrhage Diseases 0.000 claims description 9
- 208000034158 bleeding Diseases 0.000 claims description 9
- 230000000740 bleeding effect Effects 0.000 claims description 9
- 125000005842 heteroatom Chemical group 0.000 claims description 9
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 6
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000002723 alicyclic group Chemical group 0.000 claims description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000006848 alicyclic heterocyclic group Chemical group 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000002837 carbocyclic group Chemical group 0.000 claims description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 206010051077 Post procedural haemorrhage Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 125000005205 alkoxycarbonyloxyalkyl group Chemical group 0.000 claims description 2
- 125000005197 alkyl carbonyloxy alkyl group Chemical group 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 125000003566 oxetanyl group Chemical group 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000004344 phenylpropyl group Chemical group 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 13
- 108010088842 Fibrinolysin Proteins 0.000 abstract description 8
- 230000020764 fibrinolysis Effects 0.000 abstract description 8
- 229940012957 plasmin Drugs 0.000 abstract description 8
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 238000006243 chemical reaction Methods 0.000 description 142
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 104
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 96
- 238000000132 electrospray ionisation Methods 0.000 description 88
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 58
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 58
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 57
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 46
- 238000004440 column chromatography Methods 0.000 description 45
- 230000002829 reductive effect Effects 0.000 description 45
- 239000000243 solution Substances 0.000 description 42
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 39
- 239000012074 organic phase Substances 0.000 description 37
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 36
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
- 238000004809 thin layer chromatography Methods 0.000 description 28
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 26
- 239000012043 crude product Substances 0.000 description 26
- 238000000746 purification Methods 0.000 description 25
- 239000002904 solvent Substances 0.000 description 24
- 229940079593 drug Drugs 0.000 description 21
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 21
- 229940086542 triethylamine Drugs 0.000 description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
- 230000002439 hemostatic effect Effects 0.000 description 17
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 16
- 230000015556 catabolic process Effects 0.000 description 14
- 238000006731 degradation reaction Methods 0.000 description 14
- 239000012141 concentrate Substances 0.000 description 13
- 238000004128 high performance liquid chromatography Methods 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 11
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 11
- 229960000401 tranexamic acid Drugs 0.000 description 11
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 102000013566 Plasminogen Human genes 0.000 description 10
- 108010051456 Plasminogen Proteins 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 9
- 102000009123 Fibrin Human genes 0.000 description 8
- 108010073385 Fibrin Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 229950003499 fibrin Drugs 0.000 description 8
- 238000012544 monitoring process Methods 0.000 description 8
- 239000012299 nitrogen atmosphere Substances 0.000 description 8
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 7
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 7
- 239000005457 ice water Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 125000006413 ring segment Chemical group 0.000 description 7
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 6
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000010791 quenching Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- LPZHKCVGWZFNDC-UHFFFAOYSA-N tert-butyl 2-chloro-7,8-dihydro-5h-1,6-naphthyridine-6-carboxylate Chemical compound ClC1=CC=C2CN(C(=O)OC(C)(C)C)CCC2=N1 LPZHKCVGWZFNDC-UHFFFAOYSA-N 0.000 description 5
- MIHZWUHBJFMDNM-UHFFFAOYSA-N tert-butyl 2-chloro-8-hydroxy-7,8-dihydro-5H-1,6-naphthyridine-6-carboxylate Chemical compound CC(C)(C)OC(N(CC1O)CC(C=C2)=C1N=C2Cl)=O MIHZWUHBJFMDNM-UHFFFAOYSA-N 0.000 description 5
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 229960002684 aminocaproic acid Drugs 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 4
- LXCYSACZTOKNNS-UHFFFAOYSA-N diethoxy(oxo)phosphanium Chemical compound CCO[P+](=O)OCC LXCYSACZTOKNNS-UHFFFAOYSA-N 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 4
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- VWNXCCTWVAQAPL-UHFFFAOYSA-N 3-bromo-6-methoxy-2-methylpyridine Chemical compound COC1=CC=C(Br)C(C)=N1 VWNXCCTWVAQAPL-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000001567 anti-fibrinolytic effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 3
- 239000003527 fibrinolytic agent Substances 0.000 description 3
- 230000003480 fibrinolytic effect Effects 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- GTFKTYRMDAENON-UHFFFAOYSA-N tert-butyl 2-[ethyl(methoxy)phosphoryl]-7,8-dihydro-5H-1,6-naphthyridine-6-carboxylate Chemical compound CCP(C1=NC(CCN(C2)C(OC(C)(C)C)=O)=C2C=C1)(OC)=O GTFKTYRMDAENON-UHFFFAOYSA-N 0.000 description 3
- NRRADXDSPCCCRF-UHFFFAOYSA-N tert-butyl 2-chloro-7-formyl-7,8-dihydro-5H-1,6-naphthyridine-6-carboxylate Chemical compound CC(C)(C)OC(N(CC(C=C1)=C(C2)N=C1Cl)C2C=O)=O NRRADXDSPCCCRF-UHFFFAOYSA-N 0.000 description 3
- QZBVGNKIDZMRSU-UHFFFAOYSA-N tert-butyl 2-chloro-8-methylsulfonyloxy-7,8-dihydro-5H-1,6-naphthyridine-6-carboxylate Chemical compound CC(C)(C)OC(N(CC1OS(C)(=O)=O)CC(C=C2)=C1N=C2Cl)=O QZBVGNKIDZMRSU-UHFFFAOYSA-N 0.000 description 3
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical compound CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- CCBOIKKKPTZDBS-UHFFFAOYSA-N 2-chloro-3-fluoro-5,6,7,8-tetrahydro-1,6-naphthyridine Chemical compound C1NCCC2=C1C=C(F)C(Cl)=N2 CCBOIKKKPTZDBS-UHFFFAOYSA-N 0.000 description 2
- FRACHJCOMOVESL-UHFFFAOYSA-N 2-chloro-5,6,7,8-tetrahydro-1,6-naphthyridine;hydrochloride Chemical compound Cl.C1NCCC2=NC(Cl)=CC=C21 FRACHJCOMOVESL-UHFFFAOYSA-N 0.000 description 2
- SHWYVHBDJKHOHW-UHFFFAOYSA-N 2-chloro-5-fluoro-6-[(4-methoxyphenyl)methoxy]pyridine-3-carbonitrile Chemical compound C1=CC(OC)=CC=C1COC1=NC(Cl)=C(C#N)C=C1F SHWYVHBDJKHOHW-UHFFFAOYSA-N 0.000 description 2
- SUCDJGXNPUSISJ-UHFFFAOYSA-N 2-chloro-6-[(2-methylpropan-2-yl)oxycarbonyl]-7,8-dihydro-5H-1,6-naphthyridine-7-carboxylic acid Chemical compound CC(C)(C)OC(N(CC(C=C1)=C(C2)N=C1Cl)C2C(O)=O)=O SUCDJGXNPUSISJ-UHFFFAOYSA-N 0.000 description 2
- ARNJFWITWJVCPY-UHFFFAOYSA-N 2-chloro-7-(2-phenylethyl)-7,8-dihydro-6H-1,6-naphthyridin-5-one Chemical compound O=C1NC(CCC2=CC=CC=C2)CC2=C1C=CC(Cl)=N2 ARNJFWITWJVCPY-UHFFFAOYSA-N 0.000 description 2
- QDJCTHJSORGMMT-UHFFFAOYSA-N 2-ethenyl-5-fluoro-6-[(4-methoxyphenyl)methoxy]pyridine-3-carbonitrile Chemical compound C1=CC(OC)=CC=C1COC1=NC(C=C)=C(C#N)C=C1F QDJCTHJSORGMMT-UHFFFAOYSA-N 0.000 description 2
- XLNSXAKJUOZRBL-UHFFFAOYSA-N 2-methoxy-7-propyl-5,6,7,8-tetrahydro-1,6-naphthyridine Chemical compound CCCC(C1)NCC(C=C2)=C1N=C2OC XLNSXAKJUOZRBL-UHFFFAOYSA-N 0.000 description 2
- KNRKYNSCDIWLFH-UHFFFAOYSA-N 2-methoxy-7-propyl-7,8-dihydro-6H-1,6-naphthyridin-5-one Chemical compound CCCC(CC1=C2C=CC(OC)=N1)NC2=O KNRKYNSCDIWLFH-UHFFFAOYSA-N 0.000 description 2
- SFOYOSOMRXCMMJ-UHFFFAOYSA-N 2-methyl-n-(3-phenylpropylidene)propane-2-sulfinamide Chemical compound CC(C)(C)S(=O)N=CCCC1=CC=CC=C1 SFOYOSOMRXCMMJ-UHFFFAOYSA-N 0.000 description 2
- NEDGJWKNIJJCAL-UHFFFAOYSA-N 2-methyl-n-pentan-3-ylidenepropane-2-sulfinamide Chemical compound CCC(CC)=NS(=O)C(C)(C)C NEDGJWKNIJJCAL-UHFFFAOYSA-N 0.000 description 2
- CESUXLKAADQNTB-SSDOTTSWSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@](N)=O CESUXLKAADQNTB-SSDOTTSWSA-N 0.000 description 2
- YGCZTXZTJXYWCO-UHFFFAOYSA-N 3-phenylpropanal Chemical compound O=CCCC1=CC=CC=C1 YGCZTXZTJXYWCO-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- MSHFRERJPWKJFX-UHFFFAOYSA-N 4-Methoxybenzyl alcohol Chemical compound COC1=CC=C(CO)C=C1 MSHFRERJPWKJFX-UHFFFAOYSA-N 0.000 description 2
- QPANLAKDVQHLRJ-UHFFFAOYSA-N 6-benzyl-2-chloro-3-fluoro-7,8-dihydro-5H-1,6-naphthyridine Chemical compound C(C1=CC=CC=C1)N1CC=2C=C(C(=NC=2CC1)Cl)F QPANLAKDVQHLRJ-UHFFFAOYSA-N 0.000 description 2
- ZJSWKVAPSCIRIE-UHFFFAOYSA-N 6-benzyl-3-fluoro-2-[(4-methoxyphenyl)methoxy]-7,8-dihydro-5H-1,6-naphthyridine Chemical compound COC1=CC=C(COC2=C(F)C=C3CN(CC4=CC=CC=C4)CCC3=N2)C=C1 ZJSWKVAPSCIRIE-UHFFFAOYSA-N 0.000 description 2
- XQMVICDINIHBII-UHFFFAOYSA-N 6-chloro-2,3-bis(chloromethyl)pyridine Chemical compound ClCC1=CC=C(Cl)N=C1CCl XQMVICDINIHBII-UHFFFAOYSA-N 0.000 description 2
- WSSBHZAVMOMREB-UHFFFAOYSA-N 7,7-diethyl-1,5,6,8-tetrahydro-1,6-naphthyridin-2-one Chemical compound CCC(CC)(C1)NCC(C=C2)=C1N=C2O WSSBHZAVMOMREB-UHFFFAOYSA-N 0.000 description 2
- UHEUHYOWCNJUEJ-UHFFFAOYSA-N 7,7-diethyl-2-methoxy-6,8-dihydro-1,6-naphthyridin-5-one Chemical compound CCC(CC)(CC1=C2C=CC(OC)=N1)NC2=O UHEUHYOWCNJUEJ-UHFFFAOYSA-N 0.000 description 2
- NWNHAGHKVJPHSN-UHFFFAOYSA-N 7,7-diethyl-2-methoxy-6,8-dihydro-5H-1,6-naphthyridine Chemical compound CCC(CC)(C1)NCC(C=C2)=C1N=C2OC NWNHAGHKVJPHSN-UHFFFAOYSA-N 0.000 description 2
- HANMBCVDXMKZRQ-UHFFFAOYSA-N 7-(2-phenylethyl)-1,6,7,8-tetrahydro-1,6-naphthyridine-2,5-dione Chemical compound OC(C=C1)=NC(CC(CCC2=CC=CC=C2)N2)=C1C2=O HANMBCVDXMKZRQ-UHFFFAOYSA-N 0.000 description 2
- HTQDIPMFFSXPRU-UHFFFAOYSA-N 7-propyl-5,6,7,8-tetrahydro-1H-1,6-naphthyridin-2-one Chemical compound CCCC(C1)NCC(C=C2)=C1N=C2O HTQDIPMFFSXPRU-UHFFFAOYSA-N 0.000 description 2
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 2
- IXTQHIARHPUQSU-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CC(C=C2)=C1N=C2P(O)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CC(C=C2)=C1N=C2P(O)=O)=O IXTQHIARHPUQSU-UHFFFAOYSA-N 0.000 description 2
- VETKNNFYTHLFJI-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CC(C=C2)=C1N=C2P(OC)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CC(C=C2)=C1N=C2P(OC)=O)=O VETKNNFYTHLFJI-UHFFFAOYSA-N 0.000 description 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- ZGMJBCMKGIQOTE-UHFFFAOYSA-N N-[1-(3-bromo-6-methoxypyridin-2-yl)-4-phenylbutan-2-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)S(NC(CCC1=CC=CC=C1)CC1=NC(OC)=CC=C1Br)=O ZGMJBCMKGIQOTE-UHFFFAOYSA-N 0.000 description 2
- AJDZDIDNTFJJBJ-UHFFFAOYSA-N N-[3-[(3-bromo-6-methoxypyridin-2-yl)methyl]pentan-3-yl]-2-methylpropane-2-sulfinamide Chemical compound CCC(CC)(CC1=NC(OC)=CC=C1Br)NS(C(C)(C)C)=O AJDZDIDNTFJJBJ-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- AURNCCDRERCCJY-UHFFFAOYSA-N [6-chloro-2-(hydroxymethyl)pyridin-3-yl]methanol Chemical compound OCC1=CC=C(Cl)N=C1CO AURNCCDRERCCJY-UHFFFAOYSA-N 0.000 description 2
- MNZMECMQTYGSOI-UHFFFAOYSA-N acetic acid;hydron;bromide Chemical compound Br.CC(O)=O MNZMECMQTYGSOI-UHFFFAOYSA-N 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- GEBLOQXLELCEEO-UHFFFAOYSA-N bis[(2-methylpropan-2-yl)oxy]-oxophosphanium Chemical compound CC(C)(C)O[P+](=O)OC(C)(C)C GEBLOQXLELCEEO-UHFFFAOYSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
- 229940078916 carbamide peroxide Drugs 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- XEVROCIBWHZFQS-UHFFFAOYSA-N dimethyl 1-oxidopyridin-1-ium-2,3-dicarboxylate Chemical compound COC(=O)C1=CC=C[N+]([O-])=C1C(=O)OC XEVROCIBWHZFQS-UHFFFAOYSA-N 0.000 description 2
- KEKUTUAIDOVRDG-UHFFFAOYSA-N dimethyl 6-chloropyridine-2,3-dicarboxylate Chemical compound COC(=O)C1=CC=C(Cl)N=C1C(=O)OC KEKUTUAIDOVRDG-UHFFFAOYSA-N 0.000 description 2
- GPAYUJZHTULNBE-UHFFFAOYSA-O diphenylphosphanium Chemical compound C=1C=CC=CC=1[PH2+]C1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-O 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- NXMCBCQSWXBYJH-UHFFFAOYSA-N ethyl 2-[2-(tert-butylsulfinylamino)-2-ethylbutyl]-6-methoxypyridine-3-carboxylate Chemical compound CCC(CC)(CC(N=C(C=C1)OC)=C1C(OCC)=O)NS(C(C)(C)C)=O NXMCBCQSWXBYJH-UHFFFAOYSA-N 0.000 description 2
- SIEAJBLWAMMLFY-UHFFFAOYSA-N ethyl 2-[2-(tert-butylsulfinylamino)-4-phenylbutyl]-6-methoxypyridine-3-carboxylate Chemical compound CCOC(C(C=C1)=C(CC(CCC2=CC=CC=C2)NS(C(C)(C)C)=O)N=C1OC)=O SIEAJBLWAMMLFY-UHFFFAOYSA-N 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 208000031169 hemorrhagic disease Diseases 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- LFILDSDQMSCNBV-LURJTMIESA-N propane-2-sulfinamide Chemical compound CC(C)[S@@](N)=O LFILDSDQMSCNBV-LURJTMIESA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- FJINMYUMHWFOOQ-UHFFFAOYSA-N tert-butyl 2-[bis[(2-methylpropan-2-yl)oxy]phosphoryl]-7,7-diethyl-5,8-dihydro-1,6-naphthyridine-6-carboxylate Chemical compound CCC(CC)(CC1=C(C2)C=CC(P(OC(C)(C)C)(OC(C)(C)C)=O)=N1)N2C(OC(C)(C)C)=O FJINMYUMHWFOOQ-UHFFFAOYSA-N 0.000 description 2
- VQLFMSPPVJJGRU-UHFFFAOYSA-N tert-butyl 2-[bis[(2-methylpropan-2-yl)oxy]phosphoryl]-7-(2-phenylethyl)-7,8-dihydro-5H-1,6-naphthyridine-6-carboxylate Chemical compound CC(C)(C)OC(N(C1)C(CCC2=CC=CC=C2)CC2=C1C=CC(P(OC(C)(C)C)(OC(C)(C)C)=O)=N2)=O VQLFMSPPVJJGRU-UHFFFAOYSA-N 0.000 description 2
- FNBBGJRRMSWZDW-UHFFFAOYSA-N tert-butyl 2-[bis[(2-methylpropan-2-yl)oxy]phosphoryl]-7-propyl-7,8-dihydro-5H-1,6-naphthyridine-6-carboxylate Chemical compound CCCC(CC1=C(C2)C=CC(P(OC(C)(C)C)(OC(C)(C)C)=O)=N1)N2C(OC(C)(C)C)=O FNBBGJRRMSWZDW-UHFFFAOYSA-N 0.000 description 2
- PPNRZABTTCHBGW-UHFFFAOYSA-N tert-butyl 2-[methoxy(2-phenylethyl)phosphoryl]-7,8-dihydro-5H-1,6-naphthyridine-6-carboxylate Chemical compound CC(C)(C)OC(N(CC1)CC(C=C2)=C1N=C2P(CCC1=CC=CC=C1)(OC)=O)=O PPNRZABTTCHBGW-UHFFFAOYSA-N 0.000 description 2
- XCKHXCJKOTXWSX-UHFFFAOYSA-N tert-butyl 2-chloro-1-oxido-7,8-dihydro-5h-1,6-naphthyridin-1-ium-6-carboxylate Chemical compound C1=CC(Cl)=[N+]([O-])C2=C1CN(C(=O)OC(C)(C)C)CC2 XCKHXCJKOTXWSX-UHFFFAOYSA-N 0.000 description 2
- XZAIZHURLABPEI-UHFFFAOYSA-N tert-butyl 2-chloro-3-fluoro-7,8-dihydro-5H-1,6-naphthyridine-6-carboxylate Chemical compound ClC1=NC=2CCN(CC=2C=C1F)C(=O)OC(C)(C)C XZAIZHURLABPEI-UHFFFAOYSA-N 0.000 description 2
- MFMPWJIWFZSHHR-UHFFFAOYSA-N tert-butyl 2-chloro-5-oxo-7-(2-phenylethyl)-7,8-dihydro-1,6-naphthyridine-6-carboxylate Chemical compound CC(C)(C)OC(N(C(CCC1=CC=CC=C1)CC1=C2C=CC(Cl)=N1)C2=O)=O MFMPWJIWFZSHHR-UHFFFAOYSA-N 0.000 description 2
- SHFYEZSZFUAPAP-UHFFFAOYSA-N tert-butyl 2-chloro-7,7-diethyl-5,8-dihydro-1,6-naphthyridine-6-carboxylate Chemical compound CCC(CC)(CC1=C(C2)C=CC(Cl)=N1)N2C(OC(C)(C)C)=O SHFYEZSZFUAPAP-UHFFFAOYSA-N 0.000 description 2
- MNAQKPTVWIEANK-UHFFFAOYSA-N tert-butyl 2-chloro-7-(2-methylprop-1-enyl)-7,8-dihydro-5H-1,6-naphthyridine-6-carboxylate Chemical compound CC(C)(C)OC(N(CC(C=C1)=C(C2)N=C1Cl)C2C=C(C)C)=O MNAQKPTVWIEANK-UHFFFAOYSA-N 0.000 description 2
- LMVPVIZIJOYDDY-UHFFFAOYSA-N tert-butyl 2-chloro-7-[methoxy(methyl)carbamoyl]-7,8-dihydro-5H-1,6-naphthyridine-6-carboxylate Chemical compound CC(C)(C)OC(N(CC(C=C1)=C(C2)N=C1Cl)C2C(N(C)OC)=O)=O LMVPVIZIJOYDDY-UHFFFAOYSA-N 0.000 description 2
- CRLWSMRPOGIWJL-UHFFFAOYSA-N tert-butyl 2-diethoxyphosphoryl-3-fluoro-7,8-dihydro-5H-1,6-naphthyridine-6-carboxylate Chemical compound CCOP(C1=NC(CCN(C2)C(OC(C)(C)C)=O)=C2C=C1F)(OCC)=O CRLWSMRPOGIWJL-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- JMXKSZRRTHPKDL-UHFFFAOYSA-N titanium ethoxide Chemical compound [Ti+4].CC[O-].CC[O-].CC[O-].CC[O-] JMXKSZRRTHPKDL-UHFFFAOYSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- DEDKKOOGYIMMBC-UHFFFAOYSA-N 2,6-dichloro-5-fluoropyridine-3-carbonitrile Chemical compound FC1=CC(C#N)=C(Cl)N=C1Cl DEDKKOOGYIMMBC-UHFFFAOYSA-N 0.000 description 1
- XHYVBIXKORFHFM-UHFFFAOYSA-N 2-amino-6-methylbenzoic acid Chemical compound CC1=CC=CC(N)=C1C(O)=O XHYVBIXKORFHFM-UHFFFAOYSA-N 0.000 description 1
- JBKINHFZTVLNEM-UHFFFAOYSA-N 2-bromoethoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCBr JBKINHFZTVLNEM-UHFFFAOYSA-N 0.000 description 1
- SBJIXKYQHCIGHH-UHFFFAOYSA-N 2-chloro-7,7-diethyl-6,8-dihydro-5H-1,6-naphthyridine Chemical compound CCC(CC)(C1)NCC(C=C2)=C1N=C2Cl SBJIXKYQHCIGHH-UHFFFAOYSA-N 0.000 description 1
- FNEYFDFQZALKHS-UHFFFAOYSA-N 2-chloro-7-propyl-5,6,7,8-tetrahydro-1,6-naphthyridine Chemical compound CCCC(C1)NCC(C=C2)=C1N=C2Cl FNEYFDFQZALKHS-UHFFFAOYSA-N 0.000 description 1
- XPFNRRRGXGJZNX-UHFFFAOYSA-N 2-piperidin-4-yl-5-pyridin-3-yl-1,3,4-oxadiazole Chemical compound C1CNCCC1C1=NN=C(C=2C=NC=CC=2)O1 XPFNRRRGXGJZNX-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- WOFWUSNZPFBSPY-UHFFFAOYSA-N 6-benzyl-3-fluoro-2-[(4-methoxyphenyl)methoxy]-7,8-dihydro-1,6-naphthyridin-5-one Chemical compound C(C1=CC=CC=C1)N1C(C=2C=C(C(=NC=2CC1)OCC1=CC=C(C=C1)OC)F)=O WOFWUSNZPFBSPY-UHFFFAOYSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- VHIBOFWCGOAFJE-UHFFFAOYSA-N C1=CC=C[C-]1P(C1=CC=CC=C1)C1=CC=CC=C1.C1=CC=C[C-]1P(C1=CC=CC=C1)C1=CC=CC=C1.Cl.Cl.[Fe+2] Chemical compound C1=CC=C[C-]1P(C1=CC=CC=C1)C1=CC=CC=C1.C1=CC=C[C-]1P(C1=CC=CC=C1)C1=CC=CC=C1.Cl.Cl.[Fe+2] VHIBOFWCGOAFJE-UHFFFAOYSA-N 0.000 description 1
- OLZOKMBMSJTTIW-UHFFFAOYSA-N CC(N(CC(C=C1)=C(C2)N=C1Cl)C2(C(O)=O)C(O)=O)=O Chemical compound CC(N(CC(C=C1)=C(C2)N=C1Cl)C2(C(O)=O)C(O)=O)=O OLZOKMBMSJTTIW-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101100288143 Rattus norvegicus Klkb1 gene Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- YMOONIIMQBGTDU-VOTSOKGWSA-N [(e)-2-bromoethenyl]benzene Chemical compound Br\C=C\C1=CC=CC=C1 YMOONIIMQBGTDU-VOTSOKGWSA-N 0.000 description 1
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229960003318 alteplase Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- JTXJZBMXQMTSQN-UHFFFAOYSA-N amino hydrogen carbonate Chemical class NOC(O)=O JTXJZBMXQMTSQN-UHFFFAOYSA-N 0.000 description 1
- NZUIDXBVXHDCBP-UHFFFAOYSA-N aniline;phosphorous acid Chemical compound OP(O)O.NC1=CC=CC=C1 NZUIDXBVXHDCBP-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000000504 antifibrinolytic agent Substances 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- QJFKYVFGMFPPKM-UHFFFAOYSA-N carbonic acid;4-methylcyclohexan-1-amine Chemical compound OC(O)=O.CC1CCC(N)CC1 QJFKYVFGMFPPKM-UHFFFAOYSA-N 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 description 1
- YVHPHQBRUPLYOS-UHFFFAOYSA-N dichloromethane;methane Chemical compound C.ClCCl YVHPHQBRUPLYOS-UHFFFAOYSA-N 0.000 description 1
- SULWMEGSVQCTSK-UHFFFAOYSA-N diethyl hydrogen phosphite Chemical compound CCOP(O)OCC SULWMEGSVQCTSK-UHFFFAOYSA-N 0.000 description 1
- IAFSRAPRRFNEFH-UHFFFAOYSA-N dimethyl 6-acetyl-2-chloro-5,8-dihydro-1,6-naphthyridine-7,7-dicarboxylate Chemical compound CC(N(CC(C=C1)=C(C2)N=C1Cl)C2(C(OC)=O)C(OC)=O)=O IAFSRAPRRFNEFH-UHFFFAOYSA-N 0.000 description 1
- YLGIBCYHQZTFQL-UHFFFAOYSA-N dimethyl pyridine-2,3-dicarboxylate Chemical compound COC(=O)C1=CC=CN=C1C(=O)OC YLGIBCYHQZTFQL-UHFFFAOYSA-N 0.000 description 1
- XQRLCLUYWUNEEH-UHFFFAOYSA-N diphosphonic acid Chemical compound OP(=O)OP(O)=O XQRLCLUYWUNEEH-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- RRJHOMPUEYYASJ-UHFFFAOYSA-N ditert-butyl hydrogen phosphite Chemical compound CC(C)(C)OP(O)OC(C)(C)C RRJHOMPUEYYASJ-UHFFFAOYSA-N 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000001626 effect on respiratory system Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000000988 hyperfibrinolytic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 150000002668 lysine derivatives Chemical class 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- RHVNHKWMQOUSLJ-UHFFFAOYSA-N methoxymethanamine;hydrochloride Chemical compound Cl.COCN RHVNHKWMQOUSLJ-UHFFFAOYSA-N 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 231100001084 no genetic toxicology Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012829 orthopaedic surgery Methods 0.000 description 1
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- RPGWZZNNEUHDAQ-UHFFFAOYSA-N phenylphosphine Chemical compound PC1=CC=CC=C1 RPGWZZNNEUHDAQ-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical class [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000013215 result calculation Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- PNGLEYLFMHGIQO-UHFFFAOYSA-M sodium;3-(n-ethyl-3-methoxyanilino)-2-hydroxypropane-1-sulfonate;dihydrate Chemical compound O.O.[Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC=CC(OC)=C1 PNGLEYLFMHGIQO-UHFFFAOYSA-M 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- CESUXLKAADQNTB-UHFFFAOYSA-N tert-butanesulfinamide Chemical compound CC(C)(C)S(N)=O CESUXLKAADQNTB-UHFFFAOYSA-N 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- YJVXSJIDRHBQMJ-UHFFFAOYSA-N tert-butyl 3,4-dihydropyridine-2-carboxylate Chemical compound C(C)(C)(C)OC(=O)C=1CCC=CN1 YJVXSJIDRHBQMJ-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- PBIMIGNDTBRRPI-UHFFFAOYSA-N trifluoro borate Chemical compound FOB(OF)OF PBIMIGNDTBRRPI-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N valeric aldehyde Natural products CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Definitions
- the invention relates to the field of medicinal chemistry, in particular to a plasmin inhibitor, its preparation method and its application in the pharmaceutical field.
- Plasmin is a proteolytic enzyme that degrades fibrin.
- the hemostatic mechanism is triggered: vasoconstriction, platelet plug formation, initiation of the coagulation process, and eventual formation of stable fibrin.
- the fibrinolytic system is activated, which maintains a balance between the formation and cleavage of fibrin, and plays a role in maintaining vascular patency and remodeling the damaged blood vessel wall in the process of repairing damaged blood vessel walls. damage tissue (Tengborn L, M, Berntorp E. Thromb Res. 2015 Feb;135(2):231-42).
- the fibrinolytic system includes plasminogen, tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA).
- Plasminogen binds to lysine residues on the surface of fibrin and is converted to plasmin by an activator (ie, tPA) released from endothelial cells.
- Fibrinolysis inhibition can be used to treat bleeding.
- Antifibrinolytic use can reduce blood loss in cardiac surgery, trauma, orthopaedic surgery, solid organ transplantation, obstetrics and gynecology, neurosurgery and non-surgical diseases (Ng W, Jerath A, M. Anaesthesiol Intensive Ther.
- Tranexamic acid is a synthetic lysine derivative and antifibrinolytic agent that forms a reversible complex with plasminogen. By combining with plasminogen, it blocks the interaction of plasminogen and plasmin heavy chain with fibrin lysine residues, thereby preventing the combination of plasminogen and fibrin surface, thereby delaying fibrinolysis.
- Tranexamic acid has been approved for the treatment of severe menstrual bleeding and various surgical bleeding disorders, and is currently the most commonly used hemostatic drug in clinical practice. However, a large number of literature reports show that tranexamic acid is prone to gastrointestinal adverse reactions after oral administration, such as nausea, vomiting, diarrhea and indigestion, and its administration is large, which may cause complications such as epilepsy in patients.
- aminocaproic acid Other similar hemostatic drugs, such as aminocaproic acid, have problems such as rapid excretion from the human body, weak hemostatic effect, short duration of action and more toxic reactions.
- the mechanism of aminotoluic acid is the same as that of aminocaproic acid, and its effect is 4 to 5 times stronger than that of aminocaproic acid. It has a significant effect on general chronic bleeding, but has no hemostatic effect on trauma bleeding and cancer bleeding. In addition, excessive dosage can also promote thrombosis.
- Aprotinin a hemostatic drug commonly used in heart bypass surgery, was also withdrawn from the market by the FDA in 2008 because it could induce renal failure, myocardial infarction, and heart failure.
- Hemostatic drugs with other mechanisms such as carbachol, which acts on blood vessels, can induce epilepsy with repeated use; thrombin, a hemostatic drug that promotes the coagulation process, can only be used for gastrointestinal bleeding or local bleeding.
- One of the objectives of the present invention is to provide a new compound that can inhibit plasmin activity, delay fibrinolysis, and have coagulation and hemostatic activities.
- the present invention provides the compound represented by the following formula I structure, its pharmaceutically acceptable salts, hydrates, isomers, prodrugs and mixtures:
- R 1 are independently of each other selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, haloalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alicyclic, substituted or unsubstituted Unsubstituted aryl, substituted or unsubstituted aromatic heterocyclyl, or two R1 together with the attached carbon atoms form a carbocyclic ring containing 3 to 8 carbon atoms;
- R 2 is selected from hydrogen, hydroxy, halogen, substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, haloalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted Aliphatic heterocyclic group, substituted or unsubstituted aryl group, substituted or unsubstituted aromatic heterocyclic group;
- R is selected from hydrogen, halogen, substituted or unsubstituted alkyl
- R 4 is selected from hydrogen, substituted or unsubstituted amino, hydroxy, substituted or unsubstituted aryl, substituted or unsubstituted alkyl, substituted or unsubstituted aromatic heterocyclyl;
- R 5 is selected from hydrogen, substituted or unsubstituted alkyl, haloalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alicyclic heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted aryl Heterocyclyl, alkylcarbonyloxyalkyl, alkoxycarbonyloxyalkyl.
- the present invention relates to compounds represented by the following structures of formula (I'), pharmaceutically acceptable salts, hydrates, isomers, prodrugs and mixtures thereof:
- R 1 is selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, haloalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alicyclic, substituted or unsubstituted Aryl, substituted or unsubstituted aromatic heterocyclyl;
- R 2 is selected from hydrogen, hydroxyl, substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, haloalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aliphatic Heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted aromatic heterocyclyl;
- R is selected from hydrogen, halogen, substituted or unsubstituted alkyl
- R 4 is selected from hydrogen, substituted or unsubstituted amino, hydroxy, substituted or unsubstituted aryl, substituted or unsubstituted alkyl, substituted or unsubstituted aromatic heterocyclyl;
- R 5 is selected from hydrogen, substituted or unsubstituted alkyl, haloalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alicyclic heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted aryl Heterocyclyl.
- X is N.
- the R 1 described in the present invention are independently selected from hydrogen, substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 1 -C 6 alkoxy, C 1 -C 4 haloalkyl, substituted or unsubstituted C 3 -C 6 cycloalkyl, substituted or unsubstituted 4-8 membered alicyclic heterocyclyl, substituted or unsubstituted 6-10 membered aryl, substituted or unsubstituted Substituted 6-10 membered aromatic heterocyclyl, or two R1 together with the attached carbon atoms form a carbocyclic ring containing 3 to 8 carbon atoms.
- R 2 described in the present invention is selected from hydrogen, halogen, hydroxyl, substituted or unsubstituted amino, substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 1 -C 6 alkoxy, C 1 -C 4 haloalkyl, substituted or unsubstituted C 3 -C 6 cycloalkyl, substituted or unsubstituted 4-8 membered alicyclic, substituted or unsubstituted 6- 10-membered aryl, substituted or unsubstituted 6-10-membered aromatic heterocyclic group.
- R 3 described in the present invention is selected from hydrogen, fluorine, chlorine, bromine, substituted or unsubstituted C 1 -C 4 alkyl.
- R 4 described in the present invention is selected from hydrogen, substituted or unsubstituted amino, hydroxyl, substituted or unsubstituted 6-10 membered aryl, substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted 6-10 membered aromatic heterocyclic group.
- R 5 described in the present invention is selected from hydrogen, substituted or unsubstituted C 1 -C 4 alkyl, substituted or unsubstituted C 1 -C 4 haloalkyl, substituted or unsubstituted C 1 -C 4 haloalkyl C 3 -C 6 cycloalkyl, substituted or unsubstituted 4-8-membered alicyclic heterocyclic group, substituted or unsubstituted 6-10-membered aryl, substituted or unsubstituted 6-10-membered aromatic heterocyclic group, C 1 -C 4 alkylcarbonyloxy-C 1 -C 4 alkyl, C 1 -C 4 alkoxycarbonyloxy C 1 -C 4 alkyl.
- the R 1 groups described herein are independently of each other selected from hydrogen, substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 1 -C 6 alkoxy ; wherein, the substituted C 1 -C 6 alkyl group or the substituted C 1 -C 6 alkoxy group is selected from one or more hydroxyl groups, alkyl groups, cycloalkyl groups, alkoxy groups, aryl groups or substituted aryl groups is substituted with a group of radicals; in certain specific embodiments, the substituted C 1 -C 6 alkyl or substituted C 1 -C 6 alkoxy is replaced by one or more selected from the group consisting of hydroxyl, phenyl, C 1 -C 4 alkoxy, C 1 -C 4 alkoxy substituted phenyl, cyclohexyl group substitution.
- the R 1 groups described herein are independently of each other selected from hydrogen, -CH 2 OH, isobutyl, tert-butyl, -O(CH 2 ) 2 OH, -O(CH 2 ) 3 OH, -(CH 2 ) 4 OH, -CH 2 -O(CH 2 ) 3 OH, phenethyl, propyl, isopentyl, 3,3-dimethylbutyl, cyclohexylmethyl , cyclohexylethyl, phenylpropyl, 4-methoxyphenethyl.
- one of the R 1 groups is hydrogen.
- the two R1 together with the carbon atoms to which they are attached form a cyclobutyl, cyclopentyl or cyclohexyl ring.
- the R 2 group of the present invention is selected from hydrogen, halogen, hydroxy, hydroxy substituted C 1 -C 6 alkoxy, containing 1 to 3 groups selected from N, O and S A 6-membered alicyclic heterocyclic group of heteroatoms in which the S heteroatom is optionally oxidized.
- the R 2 group of the present invention is selected from hydrogen, hydroxyl, -OCH 2 CH 2 OH,
- the R2 groups described herein are selected from hydrogen .
- the R3 group of the present invention is selected from hydrogen or fluorine.
- the R 4 group of the present invention is selected from hydroxy, phenyl, C 1 -C 6 alkyl or phenyl substituted C 1 -C 6 alkyl.
- the R 4 group of the present invention is selected from hydroxy, phenyl, ethyl or phenethyl.
- the R 4 group of the present invention is selected from hydroxy, phenyl or phenethyl.
- the R 5 group of the present invention is selected from hydrogen, substituted or unsubstituted C 1 -C 4 alkyl, C 1 -C 4 alkylcarbonyloxy-C 1 -C 4 Alkyl or C 1 -C 4 alkoxycarbonyloxy C 1 -C 4 alkyl.
- the R 5 group described herein is selected from hydrogen, ethyl, methylcarbonyloxymethyl, isopropylcarbonyloxymethyl, or methoxycarbonyloxymethyl.
- the compounds of formula I described in the present invention have the following structure:
- Another object of the present invention is to provide a pharmaceutical composition
- a pharmaceutical composition comprising at least one of the aforementioned compounds, or pharmaceutically acceptable salts, hydrates, isomers, prodrugs and mixtures thereof, and at least one pharmaceutically acceptable compound Accepted excipients.
- Another object of the present invention is to provide the aforementioned compounds or their pharmaceutically acceptable salts, hydrates, isomers, prodrugs and mixtures, or pharmaceutical compositions for use in preparing medicines.
- the medicine can effectively inhibit the activity of plasmin, delay fibrinolysis, exert excellent therapeutic activities of coagulation and hemostasis, and can be used for abnormal bleeding caused by hyperfibrinolysis, surgical operation and postoperative bleeding.
- Another object of certain inventions is to provide a method of treating and/or alleviating a bleeding disease or disorder comprising administering to a patient in need thereof one or more of the foregoing pharmaceutical compositions or compounds of formula I or pharmaceutically acceptable thereof Accepted salts, hydrates, isomers, prodrugs or mixtures.
- pharmaceutically acceptable is intended only for use in contact with human and animal tissues without undue toxicity, irritation, allergic reaction or other problems or complications, and with reasonable benefit / risk ratio.
- salts refers to salts of the compounds of the present invention, prepared from compounds with specific substituents discovered by the present invention and relatively non-toxic acids or bases.
- base addition salts can be obtained by contacting the neutral forms of such compounds with a sufficient amount of base in neat solution or in a suitable inert solvent.
- acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of acid in neat solution or in a suitable inert solvent.
- the compounds of the present invention may exist in specific geometric or stereoisomeric forms.
- the present invention contemplates all such compounds.
- the term "isomers” as used herein includes cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers isomers, (D)-isomers, (L)-isomers, and racemic and other mixtures thereof, all of which are within the scope of the present invention.
- Alkyl refers to a straight-chain or branched-chain saturated aliphatic hydrocarbon group, for example: C 1 -C 4 alkyl and C 1 -C 6 alkyl refer to 1 to 4 carbon atoms and 1 to 6 carbon atoms, respectively A saturated aliphatic hydrocarbon group of carbon atoms.
- alkyl group of the present invention include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, isopentyl, 3,3-dimethylbutyl, etc. and their various isomers.
- Alkoxy refers to -O-alkyl; for example: C 1 -C 6 alkoxy refers to straight or branched alkoxy containing 1 to 6 carbons, C 1 -C 3 alkoxy The radical refers to a straight-chain alkoxy group or a branched-chain alkoxy group containing 1 to 3 carbons. Examples of alkoxy groups described in the present invention include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy and the like.
- Cycloalkyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent.
- C3 - C6 cycloalkyl refers to a cycloalkyl group containing 3 to 6 carbon atoms.
- Examples of cycloalkyl groups of the present invention include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, and the like.
- Aliphatic heterocyclyl refers to a saturated monocyclic hydrocarbon substituent wherein one or more ring atoms are substituted with heteroatoms selected from N, O, S, the remaining ring atoms are carbon, and wherein the S heteroatom is optionally Oxidized.
- "3-8 membered alicyclic heterocycle” refers to a saturated cyclic hydrocarbon substituent containing 3-8 ring atoms, wherein one or more ring atoms are replaced by heteroatoms selected from N, O, S, and the remaining rings The atoms are carbon, and the S heteroatoms therein are optionally oxidized.
- Examples of alicyclic groups in the present invention include, but are not limited to: oxetanyl, pyrrolidinyl, tetrahydrofuranyl, morpholinyl, thiomorpholinyl, Wait.
- Aromatic heterocyclyl refers to an aromatic cyclic substituent wherein one or more ring atoms are substituted with a heteroatom selected from N, O, S, and the remaining ring atoms are carbon.
- “5-6 membered aromatic heterocycle” refers to an aromatic heterocyclic group containing 5 to 6 ring atoms.
- aromatic heterocyclic groups of the present invention include, but are not limited to, pyridyl, pyrimidinyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, isoxazolyl, 1,2,4-oxadiazolyl.
- Aryl refers to an aromatic ring group, eg, "6-10 membered aryl” refers to an aromatic ring group containing 6 to 10 carbon ring atoms.
- aryl moieties described herein include, but are not limited to, phenyl, naphthyl, and the like.
- DMF means N,N-dimethylformamide
- THF means tetrahydrofuran
- Me means methyl.
- the activity of the compounds of the present invention was determined by plasma clot degradation assay and thromboelastography (TEG) assay.
- rtPA was added to human plasma or whole blood to activate plasminogen (Plasminogen), and the formed plasmin (Plasmin) could degrade fibrin, which was manifested as plasma fibrous clot and whole blood clot. Rapid degradation of blocks.
- the compounds of the present invention can effectively inhibit the fibrinolysis process, prolong the plasma clot degradation time (CLT, clot lysis time) time, and exert excellent coagulation and hemostatic activities.
- the pharmacological activity and safety of the compound of the present invention are obviously better than that of tranexamic acid, which is currently the most widely used hemostatic drug in clinical practice, and the compound is convenient to prepare, convenient for large-scale industrial production, can effectively reduce the cost of medication, and has great clinical application value.
- Step 1 Preparation of tert-butyl 2-chloro-7,8-dihydro-1,6-naphthyridine-6-(5H)-carboxylate
- Step 2 Preparation of 2-(diethoxyphosphoryl)-7,8-dihydro-1,6-naphthopyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 3 Preparation of 6-benzyl-3-fluoro-2-((4-methoxybenzyl)oxy)-7,8-dihydro-1,6-naphthyridin-5(6H)-one
- Step 4 Preparation of 6-benzyl-3-fluoro-2-((4-methoxybenzyl)oxy)-5,6,7,8-tetrahydro-1,6-naphthyridine
- Step 5 Preparation of 6-benzyl-2-chloro-3-fluoro-5,6,7,8-tetrahydro-1,6-naphthyridine
- Step 7 Preparation of 2-chloro-3-fluoro-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate tert-butyl ester
- Step 8 Preparation of 2-(diethoxyphosphoryl)-3-fluoro-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- tert-butyl 2-chloro-3-fluoro-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate 100 mg was dissolved in toluene (8 mL), followed by adding phosphorous acid Diethyl ester (97 mg), palladium acetate (16 mg), 1,1'-bis(diphenylphosphino)ferrocene (78 mg) and triethylamine (71 mg) were reacted at 110°C overnight. TLC showed essentially complete reaction. The system was concentrated under reduced pressure, and the obtained crude product was purified by column chromatography to obtain the title compound (130 mg).
- Step 9 Preparation of (3-fluoro-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)phosphonate hydrochloride
- Step 1 Preparation of (6-(tert-butoxycarbonyl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)phosphinic acid
- Step 2 Preparation of methyl (6-(tert-butoxycarbonyl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)phosphinate
- Step 3 Preparation of 2-(ethyl(methoxy)phosphoryl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 1 Preparation of 2-(Methoxy(styryl)phosphoryl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 2 Preparation of 2-(methoxy(phenethyl)phosphoryl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 3 Preparation of phenethyl (5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)phosphinate hydrochloride
- Step 1 Preparation of 2-chloro-8,8-difluoro-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 2 Preparation of 2-(di-tert-butoxyphosphoryl)-8,8-difluoro-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 3 Preparation of (8,8-difluoro-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)phosphonate hydrochloride
- Step 1 Preparation of 2-chloro-8-((methylsulfonyl)oxy)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 2 Preparation of 2-chloro-8-morpholine-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 3 Preparation of 2-(diethoxyphosphoryl)-8-morpholine-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 1 Preparation of 8-((tert-butyldimethylsilyl)oxy)-2-chloro-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 2 8-((tert-Butyldimethylsilyl)oxy)-2-(diethoxyphosphoryl)-7,8-dihydro-1,6-naphthyridine-6(5H) - Preparation of tert-butyl formate
- Step 1 8-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-2-chloro-7,8-dihydro-1,6-naphthyridine-6(5H) - Preparation of tert-butyl formate
- Step 2 8-(2-((tert-Butyldimethylsilyl)oxy)ethoxy)-2-(diethoxyphosphoryl)-7,8-dihydro-1,6- Preparation of naphthyridine-6(5H)-tert-butyl formate
- Step 3 Preparation of (8-(2-hydroxyethoxy)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)phosphonate hydrochloride
- Step 1 Preparation of 2-chloro-8-thiomorpholine-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 2 Preparation of 2-(di-tert-butoxyphosphoryl)-8-thiomorpholine-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 3 2-(Di-tert-butoxyphosphoryl)-8-(1-thiomorpholine oxide)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester preparation
- Step 4 Preparation of (8-(1-thiomorpholine)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)phosphonate hydrochloride
- Step 1 Preparation of 2-chloro-7-(2-methylprop-1-en-1-yl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 3 Preparation of 2-(diethoxyphosphoryl)-7-isobutyl-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 4 Preparation of (7-isobutyl-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)phosphonate hydrochloride
- Step 2 Preparation of N-(1-(3-bromo-6-methoxypyridin-2-yl)-5-butan-2-yl)-2-methylpropane-2-sulfinamide
- Step 3 Preparation of 2-(2-((tert-butylsulfinyl)amino)-5-butyl)-6-methoxynicotinic acid ethyl ester
- Step 4 Preparation of 2-methoxy-7-(3-propyl)-7,8-dihydro-1,6-naphthyridin-5(6H)-one
- Step 5 Preparation of 2-methoxy-7-(3-propyl)-5,6,7,8-tetrahydro-1,6-naphthyridine
- Step 6 Preparation of 7-(3-propyl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-ol
- Step 7 Preparation of 2-chloro-7-(3-propyl)-5,6,7,8-tetrahydro-1,6-naphthyridine
- Step 8 Preparation of 2-chloro-7-(3-propyl)-7,8-dihydro-1,6-naphthyridine-6-(5H)-carboxylic acid tert-butyl ester
- Step 9 Preparation of 2-(di-tert-butoxyphosphoryl)-7-propyl-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 10 Preparation of (7-propyl-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)phosphonate hydrochloride
- Step 2 Preparation of N-(1-(3-bromo-6-methoxypyridin-2-yl)-4-phenylbutan-2-yl)-2-methylpropane-2-sulfinamide
- reaction was monitored by LC-MS, quenched by adding saturated ammonium chloride solution, extracted with ethyl acetate three times, the organic phase was dried, concentrated to dryness, and purified by column chromatography to obtain the title compound (6.4 g).
- Step 3 Preparation of 2-(2-((tert-butylsulfinyl)amino)-4-phenylbutyl)-6-methoxynicotinic acid ethyl ester
- Step 4 Preparation of 6-(tert-Butylsulfinyl)-2-methoxy-7-phenethyl-7,8-dihydro-1,6-naphthyridin-5(6H)-one
- Step 7 Preparation of 2-Chloro-5-oxo-7-phenethyl-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 8 Preparation of 2-chloro-7-phenethyl-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 9 Preparation of 2-(di-tert-butoxyphosphoryl)-7-phenethyl-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 10 Preparation of (7-phenethyl-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)phosphonate hydrochloride
- Pentan-3-one (10.73 g) was weighed and dissolved in tetrahydrofuran (300 mL), tetraethyl titanate (46 g) and 2-methylpropane-2-sulfinamide (12 g) were added, and nitrogen was replaced with 3 times, heated at 65 °C for 20 hours.
- LC-MS monitored the completion of the reaction, water (30 mL) was added to the system, a large amount of solid was precipitated, suction filtered, the organic phase was dried, concentrated to dryness, and purified by column chromatography to obtain the title compound (10.8 g).
- Step 2 Preparation of N-(3-((3-bromo-6-methoxypyridin-2-yl)methyl)pentan-3-yl)-2-methylpropane-2-sulfinamide
- reaction was monitored by LC-MS, quenched by adding saturated ammonium chloride solution, extracted with ethyl acetate three times, the organic phase was dried, concentrated to dryness, and purified by column chromatography to obtain the title compound (11.3 g).
- Step 3 Preparation of 2-(2-((tert-butylsulfinyl)amino)-2-ethylbutyl)-6-methoxynicotinic acid ethyl ester
- Step 4 Preparation of 7,7-diethyl-2-methoxy-7,8-dihydro-1,6-naphthyridin-5(6H)-one
- Step 5 Preparation of 7,7-diethyl-2-methoxy-5,6,7,8-tetrahydro-1,6-naphthyridine
- Step 6 Preparation of 7,7-diethyl-5,6,7,8-tetrahydro-1,6-naphthyridin-2-ol
- Step 7 Preparation of 2-chloro-7,7-diethyl-5,6,7,8-tetrahydro-1,6-naphthyridine
- Step 8 Preparation of 2-chloro-7,7-diethyl-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 9 Preparation of 2-(di-tert-butoxyphosphoryl)-7,7-diethyl-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 10 Preparation of (7,7-diethyl-5,6,7,8-tetrahydro-naphthyridin-2-yl)phosphonate hydrochloride
- Step 1 Preparation of tert-butyl 2-chloro-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate
- Step 2 Preparation of 6-(tert-butoxycarbonyl)-2-chloro-5,6,7,8-tetrahydro-1,6-naphthyridine-1-oxide
- Step 3 Preparation of 8-acetoxy-2-chloro-7,8-dihydro-1,6-naphthopyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 4 Preparation of 2-chloro-8-hydroxy-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Dimethyl pyridine-2,3-dicarboxylate (4.90 g) was weighed and dissolved in acetonitrile (60 mL), carbamide peroxide (4.71 g) was added under ice bath, trifluoroacetic anhydride (10.5 g) was slowly added dropwise, After the addition was completed, the system became a clear solution, and the temperature was raised to room temperature to react for 4 hours. TLC showed essentially complete reaction. Quench by addition of aqueous sodium metabisulfite. Dichloromethane and water were added, the layers were separated, and the aqueous phase was extracted with a mixed solvent (DCM/MeOH). The organic phase was dried over anhydrous sodium sulfate, filtered with suction, and the filtrate was concentrated to dryness. The title compound (5.15 g) was obtained.
- Step 5 Preparation of dimethyl 6-acetyl-2-chloro-5,8-dihydro-1,6-naphthyridine-7,7(6H)-dicarboxylate
- 6-Chloro-2,3-bis(chloromethyl)pyridine (2.10g) was weighed and dissolved in N,N-dimethylformamide (15mL), followed by adding dimethyl acetamidomalonate ( 2.17g) and sodium hydride (0.40g). The reaction was carried out at room temperature for 1 hour, and sodium hydride (0.40 g, ) was added under an ice bath, and the reaction was carried out at room temperature overnight. TLC showed the reaction was complete. Ethyl acetate and water were added, the mixture was separated and extracted, and the organic phase was concentrated to dryness. The obtained crude product was purified by column chromatography to obtain the title compound (1.74 g).
- Step 7 Preparation of methyl 2-chloro-5,6,7,8-tetrahydro-1,6-naphthyridine-7-carboxylate hydrochloride
- Step 8 Preparation of 6-(tert-butyl)7-methyl 2-chloro-7,8-dihydro-1,6-naphthyridine-6,7(5H)-dicarboxylate
- Step 1 Preparation of 6-(tert-butoxycarbonyl)-2-chloro-5,6,7,8-tetrahydro-1,6-naphthyridine-7-carboxylic acid
- Step 2 Preparation of 2-chloro-7-(methoxy(methyl)carbamoyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- Step 3 Preparation of 2-chloro-7-formyl-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylic acid tert-butyl ester
- reaction system was placed in an ice bath, water was added dropwise to quench for 10 minutes, saturated sodium potassium tartrate solution (20 mL) was added, stirred for 20 minutes, extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and evaporated under reduced pressure. solvent, and the obtained crude product was purified by silica gel column chromatography to obtain the title compound (0.206 g).
- the absorption value changes with time, rising first and then decreasing.
- the median absorption value in the descending segment corresponds to the time-the median absorption value in the ascending segment corresponds to the time corresponding to the plasma clot degradation time (Clot lysis time).
- Inhibition rate % (1- Clot lysis time of negative control well/ Clot lysis time of compound well) ⁇ 100%
- the inhibitory effect of the compounds of the present invention on plasma clot degradation was determined by the above tests, and the IC 50 values of the compounds of the present invention were calculated to be lower than those of tranexamic acid.
- the compound of Example 1 of the present invention has an IC 50 value of 0.9 ⁇ M for inhibition of plasma clot degradation, which is far lower than that of the existing representative hemostatic drug tranexamic acid (the IC 50 value is 4.75 ⁇ M under the same experimental conditions).
- Test data show that the compounds of the present invention can effectively inhibit the degradation of plasma clots, have excellent coagulation and hemostatic activities, and their effective doses are far lower than the most frequently used hemostatic drugs in clinical practice, and can effectively avoid high-dose medication belts. Adverse reactions and complications from coming, have an excellent drug prospects.
- the pharmacokinetic properties of the compounds of the present invention in rats were studied by measuring the plasma drug concentration in rats after intravenous administration.
- the compound was weighed and dissolved in physiological saline to prepare a 0.2 mg/mL solution for intravenous administration.
- the drugs were administered according to the following schedule. After administration, about 200 ⁇ L of blood was collected from the jugular vein of the rats at each time point and placed in a heparin sodium anticoagulation tube. Blood samples were placed on ice after collection, and centrifuged within 1 hour to separate plasma (centrifugation conditions: 6800 g, 6 minutes, 2-8°C). The isolated plasma was stored in a -80°C freezer for biological sample analysis.
- Mobile phase A 0.1% formic acid in water.
- Mobile phase B 0.1% formic acid in acetonitrile.
- MS detection conditions electrospray ionization (ESI), positive mode, MRM scan.
- Thromboela-stogram (TEG) method was used to determine the antifibrinolytic effect of the compounds of the present invention in the hyperfibrinolytic state of human whole blood induced by rtPA (recombinant tissue plasminogen activator).
- Source of human blood All human blood used in the experiment was provided by healthy volunteers.
- test substance solution accurately weigh the test substance, and use physiological saline to configure the test substance to the following administration concentration (100 ⁇ test concentration):
- Example 6 1000, 300, 100, 30, 10, 3, 0.
- the compound of the present invention is convenient to prepare, convenient for industrialized large-scale production, and can effectively reduce the cost of medication.
- the compound of the present invention has good distribution, metabolism and excretion characteristics, and the possibility of drug-drug interaction is low, and can meet the requirements of pharmacokinetic parameters required for achieving curative effect in the human body.
- the compound of the present invention has low toxicity, has no effect on respiratory system, central nervous system and cardiovascular system, is well tolerated in single and repeated administration toxicity test, has sufficient safety window, and has no genotoxicity. It has broad clinical application prospects.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Description
时间(min) | 流动相A(%) | 流动相B(%) |
0 | 98 | 2 |
0.60 | 12 | 88 |
1.10 | 12 | 88 |
1.11 | 98 | 2 |
1.40 | 98 | 2 |
Claims (16)
- 式Ⅰ结构所示的化合物,其药学上可接受的盐、水合物、异构体、前药及混合物:其中,X选自N或CR,R=H或卤素;R 1彼此独立地选自氢、取代或未取代的氨基、取代或未取代的烷基、取代或未取代的烷氧基、卤代烷基、取代或未取代的环烷基、取代或未取代的脂杂环基、取代或未取代的芳基、取代或未取代的芳杂环基、或者两个R 1与所连接的碳原子一起形成包含3至8个碳原子的碳环;R 2选自氢、羟基、卤素、取代或未取代的氨基、取代或未取代的烷基、取代或未取代的烷氧基、卤代烷基、取代或未取代的环烷基、取代或未取代的脂杂环基、取代或未取代的芳基、取代或未取代的芳杂环基;R 3选自氢、卤素、取代或未取代的烷基;R 4选自氢、取代或未取代的氨基、羟基、取代或未取代的芳基、取代或未取代的烷基、取代或未取代的芳杂环基;R 5选自氢、取代或未取代的烷基、卤代烷基、取代或未取代的环烷基、取代或未取代的脂杂环基、取代或未取代的芳基、取代或未取代的芳杂环基、烷基羰基氧基烷基、烷氧基羰基氧基烷基。
- 根据权利要求1所述的化合物,其药学上可接受的盐、水合物、异构体、前药及混合物,所述化合物具有式I’的结构:其中,X选自N或CR,R=H或卤素;R 1选自氢、取代或未取代的烷基、取代或未取代的烷氧基、卤代烷基、取代或未取代的环烷基、取代或未取代的脂杂环基、取代或未取代的芳基、取代或未取代的芳杂环基;R 2选自氢、羟基、取代或未取代的氨基、取代或未取代的烷基、取代或未取代的烷氧基、卤代烷基、取代或未取代的环烷基、取代或未取代的脂杂环基、取代或未取代的芳基、取代或未取代的芳杂环基;R 3选自氢、卤素、取代或未取代的烷基;R 4选自氢、取代或未取代的氨基、羟基、取代或未取代的芳基、取代或未取代的烷基、取代或未取代的芳杂环基;R 5选自氢、取代或未取代的烷基、卤代烷基、取代或未取代的环烷基、取代或未取代的脂杂环基、取代或未取代的芳基、取代或未取代的芳杂环基。
- 根据权利要求2所述的化合物,其药学上可接受的盐、水合物、异构体、前药及混合物,其特征在于:所述R 1选自氢、取代或未取代的C 1-C 6烷基、取代或未取代的C 1-C 6烷氧基、C 1-C 4卤代烷基、取代或未取代的C 3-C 6环烷基、取代或未取代的4-8元脂杂环基、取代或未取代的6-10元芳基、取代或未取代的6-10元芳杂环基;所述R 2选自氢、羟基、取代或未取代的氨基、取代或未取代的C 1-C 6烷基、取代或未取代的C 1-C 6烷氧基、C 1-C 4卤代烷基、取代或未取代的C 3-C 6环烷基、取代或未取代的4-8元脂杂环基、取代或未取代的6-10元芳基、取代或未取代的6-10元芳杂环基;所述R 3选自氢、氟、氯、溴、取代或未取代的C 1-C 4烷基;所述R 4选自氢、取代或未取代的氨基、羟基、取代或未取代的6-10元芳基、取代或未取代的C 1-C 4烷基、取代或未取代的6-10元芳杂环基;所述R 5选自氢、取代或未取代的C 1-C 4烷基、取代或未取代的C 1-C 4卤代烷基、取代或未取代的C 3-C 6环烷基、取代或未取代的4-8元脂杂环基、取代或未取代的6-10元芳基、取代或未取代的6-10元芳杂环基。
- 根据权利要求1至3任意一项所述的化合物,其药学上可接受的盐、水合物、异构体、前药及混合物,其特征在于:所述烷基选自甲基、乙基、丙基、异丙基、正丁基、叔丁基;所述烷氧基选自甲氧基、乙氧基、正丙氧基、异丙氧基;所述环烷基选自环丙基、环丁基、环戊基、环戊烯基、环己基、环己烯基;所述脂杂环基选自氧杂丁环基、吡咯烷基、四氢呋喃基、吗啉基;所述芳基选自苯基、萘基;所述芳杂环基选自吡啶基、嘧啶基、咪唑基、吡唑基、噻唑基、噁唑基、异噁唑基、1,2,4-恶二唑基。
- 根据权利要求1或2所述的化合物,其药学上可接受的盐、水合物、异构体、前药及混合物,其中R 1基团彼此独立地选自氢、取代或未取代的C 1-C 6烷基、取代或未取代的C 1-C 6烷氧基;其中,所述取代的C 1-C 6烷基或取代的C 1-C 6烷氧基被一个或多个选自羟基、苯基、C 1-C 4烷氧基、C 1-C 4烷氧基取代的苯基、环己基的基团取代;或者两个R 1与所连接的碳原子一起形成环丁基、环戊基或环己基环。
- 根据权利要求5所述的化合物,其药学上可接受的盐、水合物、异构体、前药及混合物,其中R 1基团彼此独立地选自氢、-CH 2OH、异丁基、叔丁基、-O(CH 2) 2OH、-O(CH 2) 3OH、-(CH 2) 4OH、-CH 2-O(CH 2) 3OH、苯乙基、丙基、异戊基、3,3-二甲基丁基、环己基甲基、环己基乙基、苯丙基、4-甲氧基苯乙基,优选R 1基团之一是氢。
- 根据权利要求5或6所述的化合物,其药学上可接受的盐、水合物、异构体、前药及混合物,其中R 2基团选自氢、卤素、羟基、羟基取代的C 1-C 6烷氧基、包含1至3个选自N、O和S的杂原子的6元脂杂环基,其中的S杂原子可选择地被氧化。
- 根据权利要求5至8任意一项所述的化合物,其药学上可接受的盐、水合物、异构体、前药及混合物,其中R 3基团选自氢或氟。
- 根据权利要求5至9任意一项所述的化合物,其药学上可接受的盐、水合物、异构体、前药及混合物,其中R 4基团选自羟基、苯基、C 1-C 6烷基或苯基取代的C 1-C 6烷基,例如选自羟基、苯基、乙基或苯乙基,特别是选自羟基、苯基或苯乙基。
- 根据权利要求5至10任意一项所述的化合物,其药学上可接受的盐、水合物、异构体、前药及混合物,其中R 5基团选自氢、取代或未取代的C 1-C 4烷基、C 1-C 4烷基羰基氧基-C 1-C 4烷基或C 1-C 4烷氧基羰基氧基C 1-C 4烷基,特别是选自氢、乙基、甲基羰基氧基甲基、异丙基羰基氧基甲基或甲氧基羰基氧基甲基。
- 一种药物组合物,包含至少一种权利要求1-12中任一项所述的化合物,或其药学上可接受的盐、水合物、异构体、前药及混合物,和至少一种药学上可接受的辅料。
- 权利要求1-12中任一项所述化合物或其药学上可接受的盐、水合物、异构体、前药及混合物或权利要求13所述的药物组合物用于制备药物的用途。
- 根据权利要求14所述的用途,其特征在于所述药物具有凝血、止血的治疗活性。
- 根据权利要求15所述的用途,其特征在于所述药物可用于治疗纤溶亢进所致异常出血,外科手术和术后出血。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020237026099A KR20230128085A (ko) | 2020-12-31 | 2021-12-30 | 플라스민 억제제, 이를 제조하는 방법 및 이의 용도 |
JP2023540747A JP2024507433A (ja) | 2020-12-31 | 2021-12-30 | プラスミン阻害剤、そのための調製方法及びその応用 |
CN202180088567.7A CN116710440A (zh) | 2020-12-31 | 2021-12-30 | 一种纤溶酶抑制剂、其制备方法及应用 |
CA3203896A CA3203896A1 (en) | 2020-12-31 | 2021-12-30 | Plasmin inhibitor, and preparation method therefor and application thereof |
EP21914642.0A EP4273135A1 (en) | 2020-12-31 | 2021-12-30 | Plasmin inhibitor, and preparation method therefor and application thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011623062.X | 2020-12-31 | ||
CN202011623062 | 2020-12-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022143911A1 true WO2022143911A1 (zh) | 2022-07-07 |
Family
ID=82260285
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/143140 WO2022143911A1 (zh) | 2020-12-31 | 2021-12-30 | 一种纤溶酶抑制剂、其制备方法及应用 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP4273135A1 (zh) |
JP (1) | JP2024507433A (zh) |
KR (1) | KR20230128085A (zh) |
CN (1) | CN116710440A (zh) |
CA (1) | CA3203896A1 (zh) |
TW (1) | TWI810773B (zh) |
WO (1) | WO2022143911A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023231964A1 (zh) * | 2022-05-30 | 2023-12-07 | 赛诺哈勃药业(成都)有限公司 | 四氢萘啶衍生物在制备防治粘连相关疾病的药物中的应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007002013A2 (en) * | 2005-06-20 | 2007-01-04 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use |
CN101115760A (zh) * | 2005-01-10 | 2008-01-30 | 辉瑞大药厂 | 有效的激酶抑制剂吡咯并吡唑类 |
CN106458991A (zh) * | 2014-05-23 | 2017-02-22 | 豪夫迈·罗氏有限公司 | 苯磺酰胺衍生物和它们作为 rorc 调节剂的用途 |
WO2019063015A1 (zh) * | 2017-09-30 | 2019-04-04 | 正大天晴药业集团股份有限公司 | 作为RORγ抑制剂的磺酰基取代的双环化合物 |
CN110684048A (zh) * | 2018-05-31 | 2020-01-14 | 信达生物制药(苏州)有限公司 | 一种新型磷酸肌醇3-激酶抑制剂及其制备方法和用途 |
WO2020108538A1 (zh) * | 2018-11-27 | 2020-06-04 | 正大天晴药业集团股份有限公司 | 含有磺酰基结构的RORγ抑制剂 |
-
2021
- 2021-12-30 WO PCT/CN2021/143140 patent/WO2022143911A1/zh active Application Filing
- 2021-12-30 EP EP21914642.0A patent/EP4273135A1/en active Pending
- 2021-12-30 JP JP2023540747A patent/JP2024507433A/ja active Pending
- 2021-12-30 KR KR1020237026099A patent/KR20230128085A/ko unknown
- 2021-12-30 CA CA3203896A patent/CA3203896A1/en active Pending
- 2021-12-30 CN CN202180088567.7A patent/CN116710440A/zh active Pending
-
2022
- 2022-01-03 TW TW111100091A patent/TWI810773B/zh active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101115760A (zh) * | 2005-01-10 | 2008-01-30 | 辉瑞大药厂 | 有效的激酶抑制剂吡咯并吡唑类 |
WO2007002013A2 (en) * | 2005-06-20 | 2007-01-04 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use |
CN106458991A (zh) * | 2014-05-23 | 2017-02-22 | 豪夫迈·罗氏有限公司 | 苯磺酰胺衍生物和它们作为 rorc 调节剂的用途 |
WO2019063015A1 (zh) * | 2017-09-30 | 2019-04-04 | 正大天晴药业集团股份有限公司 | 作为RORγ抑制剂的磺酰基取代的双环化合物 |
CN110684048A (zh) * | 2018-05-31 | 2020-01-14 | 信达生物制药(苏州)有限公司 | 一种新型磷酸肌醇3-激酶抑制剂及其制备方法和用途 |
WO2020108538A1 (zh) * | 2018-11-27 | 2020-06-04 | 正大天晴药业集团股份有限公司 | 含有磺酰基结构的RORγ抑制剂 |
Non-Patent Citations (3)
Title |
---|
NG WJERATH AWASOWICZ M, ANAESTHESIOL INTENSIVE THER, vol. 47, no. 4, 2015, pages 339 - 50 |
TENGBOM LBLOMBACK MBERNTORP E, THROMB RES., vol. 135, no. 2, February 2015 (2015-02-01), pages 231 - 42 |
TENGBORN LBLOMBACK MBERNTORP E, THROMB RES, vol. 135, no. 2, February 2015 (2015-02-01), pages 231 - 42 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023231964A1 (zh) * | 2022-05-30 | 2023-12-07 | 赛诺哈勃药业(成都)有限公司 | 四氢萘啶衍生物在制备防治粘连相关疾病的药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
JP2024507433A (ja) | 2024-02-20 |
EP4273135A1 (en) | 2023-11-08 |
TWI810773B (zh) | 2023-08-01 |
TW202233199A (zh) | 2022-09-01 |
KR20230128085A (ko) | 2023-09-01 |
CN116710440A (zh) | 2023-09-05 |
CA3203896A1 (en) | 2022-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2659045T3 (es) | Derivados de oxopiridina sustituidos | |
JP2018519343A (ja) | プロテインキナーゼのモジュレーターとしてのキラルジアリール大環状分子 | |
KR102494647B1 (ko) | 비시클릭 헤테로아릴 치환된 화합물 | |
ES2694297T3 (es) | Formas cristalinas de ácido {[1-ciano-5-(4-clorofenoxi)-4-hidroxi-isoquinolina-3-carbonilo]-amino}-acético | |
WO2018133793A1 (zh) | 凝血因子XIa抑制剂及其用途 | |
JP2013525286A (ja) | タンパク質チロシンキナーゼ活性の阻害剤 | |
WO2022143911A1 (zh) | 一种纤溶酶抑制剂、其制备方法及应用 | |
KR20150023536A (ko) | 크로만 화합물 | |
TW201722965A (zh) | 用於抗菌應用之化合物 | |
TWI803177B (zh) | 一種纖維蛋白溶酶抑制劑、其製備方法及應用 | |
JPS63152374A (ja) | ヒドロキシブテノライド誘導体およびその製造法 | |
KR20170095243A (ko) | Pi3kbeta 저해제로서의 헤테로사이클릴 연결된 이미다조피리다진 유도체 | |
WO2021104413A1 (zh) | 稠合吡啶环衍生物、其制备方法及其在医药上的应用 | |
JP2019518032A (ja) | Pi3k beta阻害薬としての二環式ピリジン、ピラジンおよびピリミジン誘導体 | |
CN113135929A (zh) | 呋喃并吡啶酮酰胺化合物及其制备方法和用途 | |
CN104530046A (zh) | 二氮杂螺类化合物及其在药物中的应用 | |
JPWO2006106804A1 (ja) | 環内窒素原子にアシル基が結合した三環系スピロ化合物 | |
CN112778273B (zh) | 环酮并吡啶酮类化合物及其制备方法和用途 | |
CN114853814A (zh) | 一种纤溶酶抑制剂、其制备方法及应用 | |
WO2022052926A1 (zh) | 芳香乙烯类化合物、其制备方法、中间体、药物组合物及其应用 | |
CN115703776A (zh) | 一种纤溶酶抑制剂、其制备方法及应用 | |
WO2024061365A1 (zh) | 嘧啶并环类化合物及其制备方法与用途 | |
CN104530031A (zh) | 噁唑烷酮类化合物及其在药物中的应用 | |
WO2023197984A1 (zh) | 稠环化合物、包含其的药物组合物及应用 | |
TW202340189A (zh) | 含有肼基的化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21914642 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3203896 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180088567.7 Country of ref document: CN Ref document number: 2023540747 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 20237026099 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021914642 Country of ref document: EP Effective date: 20230731 |